Drug Type Antibody drug conjugate (ADC) |
Synonyms NN-3201 |
Target |
Mechanism Tubulin inhibitors, c-Kit inhibitors(Stem cell growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Novelty Nobility, Inc.Startup |
Active Organization Novelty Nobility, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrointestinal Stromal Tumors | Phase 1 | - | Novelty Nobility, Inc.Startup | - |
Small Cell Lung Cancer | Phase 1 | - | Novelty Nobility, Inc.Startup | - |
Acute Myeloid Leukemia | Preclinical | KR | Novelty Nobility, Inc.Startup | 27 Jul 2022 |
Philadelphia chromosome positive chronic myelogenous leukemia | Preclinical | KR | Novelty Nobility, Inc.Startup | 27 Jul 2022 |